PLCL2 Antibody, HRP conjugated
-
中文名稱：PLCL2兔多克隆抗體, HRP偶聯
-
貨號：CSB-PA892366LB01HU
-
規格：￥880
-
其他：
產品詳情
-
產品名稱：Rabbit anti-Homo sapiens (Human) PLCL2 Polyclonal antibody
-
Uniprot No.：
-
基因名：PLCL2
-
別名：FLJ13484 antibody; Inactive phospholipase C like protein 2 antibody; Inactive phospholipase C-like protein 2 antibody; KIAA1092 antibody; Phospholipase C epsilon 2 antibody; Phospholipase C L2 antibody; Phospholipase C like 2 antibody; Phospholipase C-epsilon-2 antibody; Phospholipase C-L2 antibody; PLC epsilon 2 antibody; PLC L(2) antibody; PLC L2 antibody; PLC-epsilon-2 antibody; PLC-L(2) antibody; PLC-L2 antibody; PLCE 2 antibody; PLCE2 antibody; PLCL 2 antibody; PLCL2 antibody; PLCL2_HUMAN antibody
-
宿主：Rabbit
-
反應種屬：Human
-
免疫原：Recombinant Human Inactive phospholipase C-like protein 2 protein (2-300AA)
-
免疫原種屬：Homo sapiens (Human)
-
標記方式：HRP
-
克隆類型：Polyclonal
-
抗體亞型：IgG
-
純化方式：>95%, Protein G purified
-
濃度：It differs from different batches. Please contact us to confirm it.
-
保存緩沖液：Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4 -
產品提供形式：Liquid
-
應用范圍：ELISA
-
Protocols：
-
儲存條件：Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期：Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
-
用途：For Research Use Only. Not for use in diagnostic or therapeutic procedures.
產品評價
相關產品
靶點詳情
-
功能：May play an role in the regulation of Ins(1,4,5)P3 around the endoplasmic reticulum.
-
基因功能參考文獻：
- PLCL2 was identified as a new susceptibility gene for systemic sclerosis. PMID: 25880423
- A genome-wide association study identifies PLCL2 and AP3D1-DOT1L-SF3A2 as new susceptibility loci for myocardial infarction in Japanese PMID: 24916648
-
亞細胞定位：Cytoplasm.
-
數據庫鏈接：
Most popular with customers
-
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
-
-
-
-
-
